2.Clinical effect of the application of microscopic pterygium resection combined with different concentration of mitomycin C
Fei, XUE ; Wen-Gang, XU ; Xin, DAI ; Jun-Wei, LUO ; Jin-Ying, CAO ; Dao-Rong, SHENG
International Eye Science 2014;(12):2277-2279
AlM: To study the clinical effect of the application of microscopic pterygium resection combined with different concentration of mitomycin C ( MMC) .
METHODS:A total of 110 cases of pterygium patients (120 eyes) were randomly divided into control group (58 eyes) and observation group (62 eyes) according to the odd and even number method. The control group adopted the pterygium resection combined 0. 3mg/mL MMC, and the observation group was given pterygium resection combined 0. 2mg/mL MMC. The cure rate and the recurrence rate, eyesight before and after the treatment, two groups of cornea and sclera wound healing situation, the incidence of postoperative complications were compared.
RESULTS: The cure rate and recurrence rate of the control group was 84. 5% and 15. 5% respectively, and the observation group was 93. 6% and 6. 5% respectively, the differences were statistically significant (P<0. 05). There were statistical differences of vision of the two groups before and after treatment (P<0. 05), and there were no statistical differences of the two groups between the two groups after treatment (P>0. 05). The cornea, sclera, wound healing time of the observation group were less than the control group, and there were statistical differences between the two groups ( P < 0. 05 ). The incidence of complications was 13. 8% in the control group and 3. 2% in observation group, with statistically significant difference (P<0. 05).
CONCLUSlON: The application effect of microscopic pterygium resection combined with MMC is remarkable, and the joint of 0. 2mg/mL concentration of MMC is more safe and effective, and is worth popularizing in clinical application.
3.Combined anti-tumor therapeutic effect of targeted gene, hyperthermia, radionuclide brachytherapy in breast carcinoma
Dao-zhen, CHEN ; Qiu-sha, TANG ; Jing-ying, XIANG ; Fei, XU ; Li, ZHANG ; Jun-feng, WANG
Chinese Journal of Nuclear Medicine 2011;31(2):82-86
Objective To investigate the antitumor therapeutic effect of combined therapy of magnetic induction heating by nano-magnetic particles, herpes simplex virus thymidine kinase gene(HSV-tk suicide gene) and internal radiation in mice bearing MCF-7 breast carcinoma. Methods The transfection reagents, plasmids heat shock protein-HSV-tk (pHSP-HSV-tk), ferroso-ferric oxide nano-magnetic fluid flow and 188Re-ganciclovir-bovine serum albumin-nanopaticles (GCV-BSA-NP) were prepared. The heating experiments in vivo were carried out using ferroso-ferric oxide nano-magnetic fluid flow. Sixty mice tumor models bearing MCF-7 breast carcinoma were established and randomly divided into six groups. Group A was the control group, B was gene transfection therapy group, C was hyperthermia group, D was gene transfection therapy combined with radionuclide brachytherapy group, E was gene therapy combined with hyperthermia group, and F was gene therapy, hyperthermia combined with radionuclide brachytherapy group. The tumor growth, tumor mass and histopathological changes were evaluated. The expression of HSV-tk in the groups of B, D, E and F was detected by RT-PCR. Poisson distribution and one-way analysis of variance (ANOVA) were used for statistical analysis by SPSS 10.0 software. Results In the animal heating experiments, the temperature of tumor increased up to 39.6 ℃, 43.2 ℃, and 48.1 ℃ quickly with different injected doses (2, 4 and 6 mg respectively) of nano-magnetic particles and maintained for 40 min. The temperature of tumor tissue reduced to 36.8 ℃, 37.5 ℃ and 37.8 ℃ in 10 min when alternating magnetic field (AMF) stopped. The tumor mass in Groups C ((452.50 ±30.29) mg), D ((240.98 ±35.32)mg), E((231.87 ±27.41) mg) and F ((141.55 ±23.78) mg) were much lower than that in Group A ((719.12±22.65) mg) (F=800.07, P<0. 01), with the most significant treatment effect in Group F.The tumor mass in Group B((684.05 ±24.02) mg) was higher than that in Group D (t =32. 805, P <0. 05). Semi-quantitative RT-PCR analysis showed that the expression of HSV-tk in Groups B and D (0.33 ±0. 13 and 0. 46 ±0.12) was significantly different from that in Groups E and F (0.66 ±0.13 and 0.74 ±0. 11)(F = 21. 573, P < 0.05). Conclusion Combined use of hyperthermia, gene therapy and radionuclide brachytherapy could effectively depress the growth of MCF-7 breast carcinoma, thus possessing treatment potential for this tumor.
5.Study on Clinical Consistency Evaluation in TCM Practice Guidelines for Prevention and Treatment of Biqiu (Allergic Rhinitis)
Hao XU ; Hong-Jun DONG ; Xu-Qing CHEN ; Dao-Nan YAN
Chinese Journal of Information on Traditional Chinese Medicine 2018;25(3):16-18
Zhangjiagang Hospital of Traditional Chinese Medicine, as a collaborative unit of the project, participated in the clinical consistency evaluation in project of TCM Practice guidelines for Prevention and Treatment of Biqiu (allergic rhinitis) organized by the State Administration of Traditional Chinese Medicine. The evaluation results showed that the guideline met the clinical practice requirements. This article summarized the clinical evaluation experience from the three aspects: The diagnosis in TCM and Western medicine is clear and definite, but the English translation needs to be considered; The definition of remission phase of Biqiu (allergic rhinitis) is difficult, to interfere by identifying the constitution is innovative; The advantages of "preventive treatment of diseases" in TCM should be fully played in role, improving the satisfaction of patients.
6.Effect of hepatitis C virus serotype on the response of patients with chronic hepatitis C to interferon treatment.
Li-jun CHEN ; Ming-hui LI ; Yao XIE ; Dao-zhen XU
Chinese Journal of Experimental and Clinical Virology 2007;21(2):117-119
OBJECTIVETo investigate the influence of hepatitis C virus (HCV) serotype on the interferon (IFN) treatment of patients with chronic hepatitis C.
METHODSNinety-eight patients with chronic hepatitis C were divided into two groups: patients in group 1 (n=53) were treated with Pegasys, 180 ug injected subcutaneously once a week for 24 weeks, and those in group 2 (n=45) were injected with Roferon-A 3 MU three times a week for 24 weeks and then patients in both groups were followed up for another 24 weeks. The virological response at the end of follow up was the primary endpoint for evaluating the effects of IFN treatment. The HCV RNA levels of the chronic hepatitis C patients were determined with COBAS AMPLICOR MONITOR Test, version 2.0, and the HCV serotypes were examined by the means of ELISA using Murex HCV Serotyping 1-6 Assay.
RESULTSOf the 98 cases, HCV in 44 cases was serotype 1, in 23 was serotype 2, in 10 was serotype 3, in 1 was serotype 4, 1 was serotype 5 and in 2 was serotype 6; HCV serotypes in the remaining 17 patients could not determined. In Pegasys treatment group, the biochemical and virological response was not significantly different at the end of treatment between the patients with serotype 1 and non serotype 1 or serotype undetermined patients, but the sustained virological response rate of HCV serotype undetermined group (66.7 percent) was significantly higher than that of serotype 1 patients (27.3 percent) (p=0.035). In Roferon-A treatment group, the virological response rate at 24 weeks and sustained viral response rate at the end of follow-up was not significantly different between serotype 1 and non serotype 1 patients or serotype undetermined patients.
CONCLUSIONAfter the six months treatment course, the HCV serotype had some effects on the treatment response to Pegasys treatment for chronic hepatitic C.
Adult ; Antiviral Agents ; administration & dosage ; Drug Administration Schedule ; Female ; Hepacivirus ; drug effects ; immunology ; Hepatitis C Antibodies ; blood ; Hepatitis C, Chronic ; drug therapy ; immunology ; Humans ; Interferons ; administration & dosage ; Male ; Middle Aged ; Young Adult
7.Studies on formulations of Panax notoginsenosides for intranasal administration.
Qing-fang XU ; Xiao-ling FANG ; Dao-feng CHEN ; Jun-chan LI
Acta Pharmaceutica Sinica 2003;38(11):859-862
AIMTo develop high bioavailability preparations without irritation for Panax notoginsenosides.
METHODSThe effects of some additives such as microcrystalline cellulose, beta-cyclodextrin and hydroxypropyl cellulose on drug in the preparations were examined.
RESULTSSaponins of Panax notoginseng (PNS) was absorbed in rabbits more when administered intranasally than through other routines, and the formulations including MCC both gave high bioavailability and low irritation.
CONCLUSIONBioavailability of Panax notoginsenosides can be increased through changing routine of administration and formulations.
Administration, Intranasal ; Animals ; Biological Availability ; Bufo bufo ; Cellulose ; toxicity ; Cyclodextrins ; Drug Carriers ; Drug Delivery Systems ; Female ; Ginsenosides ; administration & dosage ; isolation & purification ; pharmacokinetics ; Male ; Nasal Mucosa ; metabolism ; Panax ; chemistry ; Permeability ; Rabbits ; Rats ; beta-Cyclodextrins
8.Cloning and analysis of phage Fab antibodies of mouse male specific antigen.
Nai-Dong WANG ; Li-Qun XUE ; Dao-Jun XU ; An-Wen YUAN ; Zhi-Bang DENG ; Shu-Liang CUI
Chinese Journal of Biotechnology 2006;22(5):727-732
To clone mouse phage antibodies against H-Y antigen from a phage antibody library, three cycles of affinity enrichment of the mouse phage antibody library with male spleen cells and two cycles of nonspecific absorption with female spleen cells were performed. The presence of mouse Fab on the phage surface was determined by ELISA and sequence analysis. 9 of 15 strains can bind to male spleen cells with the specific activity. Recombination rate of the phage antibody library clones is 60%. Sequence analysis of the PCR products of plasmid DNA of E5 clones show VH and Vkappa had common characteristics shared by other known variable region of antibodies. The mouse phage Fab antibody could be used for identifying H-Y antigen, and for the development of sex determination of early embryos in mammals.
Animals
;
Base Sequence
;
Cloning, Molecular
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
H-Y Antigen
;
analysis
;
Immunoglobulin Fab Fragments
;
genetics
;
immunology
;
Isoantibodies
;
genetics
;
immunology
;
Male
;
Mice
;
Molecular Sequence Data
;
Peptide Library
9.Analysis of peripheral blood lymphocyte subsets and relevant prognostic factors of 34 newly diagnosed multiple myeloma patients.
Miao CHEN ; Ying XU ; Hui LI ; Jing XIE ; Bing HAN ; Ming-hui DUAN ; Dao-bin ZHOU ; Shu-jie WANG ; Yong-qiang ZHAO ; Jun-ling ZHUANG
Chinese Journal of Hematology 2013;34(4):355-358
Aged
;
Female
;
Humans
;
Male
;
Middle Aged
;
Multiple Myeloma
;
diagnosis
;
immunology
;
Prognosis
;
T-Lymphocyte Subsets
;
immunology
10.Pharmacokinetics of antithymocyte globulin in recipients under-going HLA partially matched hematopoietic stem cell transplantation.
Xiao-Hui ZHANG ; Xiao-Jun HUANG ; Kai-Yan LIU ; Lan-Ping XU ; Dai-Hong LIU ; Dao-Pei LU
Journal of Experimental Hematology 2007;15(1):152-155
The aim of study was to investigate the pharmacokinetics and distribution of antithymocyte globulin (ATG) in recipients of partially HLA-matched hematopoietic stem cell transplantation. Fifteen patients with hematological disorders were received hematopoietic stem cell transplantation from partially HLA-matched related donor between October 2003 and October 2004 in the Institute of Hematology and People Hospital, Peking University. All patients including 5 cases of AML, 6 cases of CML, 3 cases of ALL, 1 case of AA were consecutively enrolled in the present study after providing written informed consent. Antithymocyte globulin was administered before allogeneic hematopoietic stem cell transplantation at a dose of 2.5 mg/kg daily for 4 consecutive days (total dose of 10 mg/kg) in the conditioning regimen. The concentration of rabbit ATG in the serum of 15 patients was measured using a new enzyme-linked immunoabsorbent assay (ELISA) for the Fc portion of rabbit IgG. The results showed that the washout phase of ATG elimination was analyzed over 0 - 120 days, results were well-fitted by a single exponential decay giving a mean elimination half-life (t(1/2) beta) of 29.67 +/- 2.60 days. A mean value for the apparent volume of distribution of ATG (V) obtained by analysis of data was 0.12 +/- 0.02 L/kg body weight. The serum concentration of ATG increased up to 44.8% at 5 day before transplantation, peak concentration of ATG was 136.0 +/- 10.3 mg/L, its concentration slowly descend at 0 day, fall up to 7.1 +/- 0.06 microg/ml at 90 day after dosing; t(max) 4.8 +/- 0.7 days; According to AIC (Akaike's information criterion), two compartment model of ATG was estimated. It is concluded that the conditioning regimen containing the dosage of 10 mg/kg of ATG is effective and safely in recipients of partially HLA-matched hematopoietic stem cell transplantation. There is no racial difference in the pharmacokinetics of ATG.
Adolescent
;
Adult
;
Antilymphocyte Serum
;
metabolism
;
Child
;
Female
;
Hematopoietic Stem Cell Transplantation
;
Histocompatibility Testing
;
Humans
;
Male
;
Middle Aged
;
Tissue Distribution